Screener
BridgeBio Pharma BBIO Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Repurchase of RSU shares to satisfy tax withholding | (8,341) | (3,771) |
| Proceeds from stock option exercises, net of repurchases | 27,812 | 9,680 |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Transactions with noncontrolling interests | — | 1,550 |
| Net cash provided by financing activities | 401,125 | 362,369 |
| Net increase in cash, cash equivalents, and restricted cash | 107,896 | 67,856 |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $680,036 | $751,100 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's cash and cash equivalents, end of period?
- BridgeBio Pharma (BBIO) reported cash and cash equivalents, end of period of $680.04M in Q2 2026.
- How has BridgeBio Pharma's cash and cash equivalents, end of period changed year-over-year?
- BridgeBio Pharma's cash and cash equivalents, end of period decreased by 9.5% year-over-year, from $751.1M to $680.04M.
- What is the long-term trend for BridgeBio Pharma's cash and cash equivalents, end of period?
- Over 2 years (2023 to 2025), BridgeBio Pharma's cash and cash equivalents, end of period has grown at a 20.4% compound annual growth rate (CAGR), from $394.73M to $572.14M.
- What does cash and cash equivalents, end of period mean?
- Cash and cash equivalents, end of period
Ask your AI about BridgeBio Pharma's cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude